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ABSTRACT: Benzothiazinones (BTZs) are antitubercu-
losis drug candidates with nanomolar bactericidal activity
against tubercle bacilli. Here we demonstrate that BTZs
are suicide substrates of the FAD-dependent decaprenyl-
phosphoryl-β-D-ribofuranose 2′-oxidase DprE1, an enzyme
involved in cell-wall biogenesis. BTZs are reduced by
DprE1 to an electrophile, which then reacts in a near-
quantitative manner with an active-site cysteine of DprE1,
thus providing a rationale for the extraordinary potency of
BTZs. Mutant DprE1 enzymes from BTZ-resistant strains
reduce BTZs to inert metabolites while avoiding covalent
inactivation. Our results explain the basis for drug
sensitivity and resistance to an exceptionally potent class
of antituberculosis agents.
The increasing number of drug-resistant Mycobacteriumtuberculosis strains that fail to respond to first- and second-
line drug treatment demands the development of new anti-
tuberculosis drugs.1−3 Benzothiazinones (BTZs) such as
BTZ043 (Figure 1A) are a promising class of new compounds
that kill M. tuberculosis in vitro, ex vivo, and in mouse models
of tuberculosis.4 The minimal inhibitory concentration (MIC)
of BTZ043 against M. tuberculosis is 1 ng/mL, which is
significantly lower than the MICs of all currently used
tuberculosis drugs and drug candidates. Decaprenylphosphor-
yl-β-D-ribofuranose 2′-epimerase was identified as a BTZ target
(Figure 1B).4 The enzyme is constituted of DprE1 and DprE2
that together catalyze the epimerization of decaprenylphos-
phoryl-β-D-ribofuranose (DPR) to decaprenylphosphoryl-β-D-
arabinofuranose (DPA), the arabinosyl donor for the biosyn-
thesis of mycobacterial cell wall arabinan polymers.4−6 The
reaction is believed to proceed via the keto intermediate
decaprenylphosphoryl-D-2′-keto-erythro-pentofuranose (DPX)
(Figure 1B).5 The Cys387Gly and Cys387Ser point muta-
tions in DprE1 result in 250- and 10 000-fold increases in the
MIC, respectively.4 We previously isolated a covalent adduct of
DprE1 and BTZ043 from mycobacteria incubated with
BTZ043 and proposed a mechanism of action involving
reduction of the essential nitro group of BTZ043 to a nitroso
group that then reacts with Cys387 of DprE1 to form a stable
semimercaptal (Figure 1A).7 However, the mechanism of
action of BTZs still poses numerous questions, as it is unclear
how BTZs are activated and what the basis of the specificity of
the proposed nitroso derivative for DprE1 is. Furthermore, it
has not been elucidated whether the observed modification of
DprE1 indeed affects the activity of DprE1 or functions by
inhibiting the activity of DprE2 (or both); neither have the
exact roles of DprE1 and DprE2 in the epimerization reaction
been validated.
A more detailed characterization of the mechanism of action
of BTZs requires the availability of pure DprE1 and DprE2. As
our previous attempts to purify recombinant DprE1 and DprE2
of M. tuberculosis H37Rv in their active form were unsuccessful,
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Figure 1. BTZs and decaprenylphosphoryl-β-D-ribofuranose 2′-
epimerase. (A) Structures of BTZ043 and its nitroso and semi-
mercaptal derivatives. (B) Epimerization of decaprenylphosphoryl-β-D-
ribofuranose (DPR) to decaprenylphosphoryl-β-D-arabinofuranose
(DPA) via decaprenylphosphoryl-D-2′-keto-erythro-pentofuranose
(DPX).
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we cloned the orthologous genes MSMEG_6382 and
MSMEG_6385 of Mycobacterium smegmatis strain mc2155
for heterologous expression in Escherichia coli (E. coli). The
corresponding M. smegmatis proteins DprE1SM and DprE2SM
share 81% and 85% sequence identity with their M. tuberculosis
H37Rv counterparts DprE1 and DprE2, respectively [Figure
S1A,B in the Supporting Information (SI)].
Furthermore, mutation of Cys394 in DprE1SM (correspond-
ing to Cys387 in DprE1 of M. tuberculosis H37Rv) results in
resistance of M. smegmatis toward BTZs. DprE1SM and
DprE2SM were expressed in E. coli and purified to >95%
homogeneity (Figure S1C,D). DprE1SM was isolated to ∼45%
with bound flavin adenine dinucleotide (FAD), confirming its
annotation as a FAD-dependent oxidoreductase (Figure S2).
The activity of the purified DprE1SM and DprE2SM was
confirmed by epimerization of decaprenylphosphoryl-[14C]-β-
D-ribofuranose (14C-DPR; see the SI) to 14C-DPA (Figure 2A, lane 1).
Epimerization required the presence of both proteins and
nicotinamide adenine dinucleotide (NADH) as a cofactor
(Figure S3A). In the absence of DprE2SM, partial conversion of
14C-DPR to 14C-DPX was observed (Figure 2A, lane 4).
Addition of NAD+ or NADH was not required for the
conversion of 14C-DPR to 14C-DPX by DprE1SM (Figure S3B).
In the absence of DprE1SM and the presence of NADH,
DprE2SM efficiently reduced
14C-DPX to 14C-DPA (Figure 2A,
lane 8; Figure S3B, lane 4). Together, these data demonstrate
(i) that DprE1SM oxidizes
14C-DPR to 14C-DPX using FAD as a
cofactor, (ii) that DprE2SM reduces
14C-DPX to 14C-DPR using
NADH, and (iii) that the two enzymes can function
independently (Figure 2B). We then examined the effect of
BTZ on the epimerization of 14C-DPR by DprE1SM and
DprE2SM. BTZ043 inhibited the epimerization of
14C-DPR into
14C-DPA (Figure 2A, lanes 2 and 3). In contrast, BTZ did not
inhibit the reduction of 14C-DPX to 14C-DPA by DprE2SM
(Figure 2A, lane 7). Furthermore, inhibition of the partial
conversion of 14C-DPR into 14C-DPX by BTZ was observed
(Figure 2A, lane 5). These data suggest that BTZs target DprE1
without affecting the activity of DprE2SM and that DprE1SM is
responsible for the activation of the drug.
The difficulties in producing sufficient amounts of 14C-DPR
as well as its analysis precluded its use in more detailed
mechanistic studies. We found that farnesylphosphoryl-β-D-
ribofuranose (FPR), which can be readily synthesized in greater
quantities (see the SI), is an alternative substrate that is also
epimerized by DprE1SM and DprE2SM (Figure S3C).
Incubation of DprE1SM with FPR and analysis of the reaction
mixture by HPLC and mass spectrometry (MS) permitted the
isolation of a main reaction product with an exact mass of
431.1838 Da [M − H]. This corresponds to the mass of the 2-
keto derivative farnesylphosphoryl-D-2′-keto-erythro-pentose
(FPX) with a mass of 431.1835 Da [M − H] (Figure S3D).
The data lend further support to an epimerization mechanism
in which DprE1SM, using FAD as a cofactor, independently
oxidizes FPR or DPR to the corresponding D-2′-keto-erythro-
pentose, which is then reduced by DprE2SM to FPA or DPA
using NADH (Figure 2B).
For the detection of the proposed covalent BTZ−DprE1
adduct, we synthesized a fluorescently labeled BTZ derivative,
BTZ-BODIPY-X (Figure 2C) (see the SI). Only weak
fluorescent labeling of DprE1SM was observed upon incubation
of DprE1SM with BTZ-BODIPY-X at 10 μM (Figure 2C, lane 2).
However, the efficiency of the fluorescent labeling was increased
about 8-fold upon addition of the DprE1SM substrate FPR to the
reaction mixture (Figure 2D, lane 1). Furthermore, fluorescent
labeling could be suppressed or reversed by (i) heat inactivation
of DprE1SM, (ii) prior incubation with BTZ043, or (iii) subsequent
incubation with an excess of thiols under denaturing conditions
(Figure 2D, lanes 3−5). Together, thesedata suggest that DprE1SM
is capable of reducing BTZ-BODIPY-X to the corresponding
electrophilic nitroso derivative, which then specifically reacts with
DprE1SM to form a covalent complex. We assume that reduction of
the nitro group of BTZ-BODIPY to the nitroso derivative
requires the presence of FADH2. This then explains the
dependence of the labeling on the presence of FPR, which
is needed to generate FADH2. There is literature precedent
for the reduction of nitro groups by FAD-dependent
enzymes: bacterial oxygen-insensitive nitroreductases such
as NfsA and NfsB from E. coli and NfnB from M. smegmatis
use flavin as redox cofactor for the reduction of nitro-
aromatic compounds.8−10
The reversal of the labeling by incubation of denatured,
labeled DprE1SM with excess thiols is in agreement with the
formation of a semimercaptal from the nitroso derivative of
Figure 2. Characterization of DprE1SM and DprE2SM and their
interactions with BTZ043. (A) TLC analysis of the conversion of 14C-
DPR or 14C-DPX to 14C-DPA by DprE1SM and/or DprE2SM in the
presence or absence of BTZ043 (58 μM). All reactions were done at pH
7.9 in the presence of NAD+ and NADH (both at 50 μM). Visualization
of 14C-labeled substrates was effected by means of autoradiography.
Lane 2: Enzymes were incubated with BZT043 for 1 h before substrate
was added. * denotes lane 3 as in lane 2 but without BTZ preincubation.
(B) Functions of DprE1SM and DprE2SM in the epimerization of DPR
(FPR) to DPA (FPA). (C) Structure of the fluorescent derivative BTZ-
BODIPY-X. (D) Fluorescence labeling of DprE1SM and
G394DprE1SM by
BTZ-BODIPY-X (10 μM). Labeling was analyzed by SDS-PAGE and in-
gel fluorescence scanning. Coomassie staining of the gel is shown for
comparison. * denotes the use of heat-denatured DprE1SM; ** denotes
post-treatment with 20 mM DTT/7 M urea.
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BTZ-BODIPY-X and Cys394 of DprE1SM, as semimercaptals
are labile to thiols.11−13 To lend further support to the
hypothesis that fluorescent labeling of DprE1SM occurs on
Cys394, we prepared the mutant Cys394Gly (G394DprE1SM)
and incubated it with BTZ-BODIPY-X and FPR. No significant
labeling of G394DprE1SM under these conditions could be
detected. Finally, no fluorescent labeling of DprE2SM by BTZ-
BODIPY-X could be detected (Figure S4).
To confirm the proposed formation of a semimercaptal
between BTZ043 and DprE1SM, we analyzed the covalent
complex by MS. Analysis of the covalent drug−protein complex
required its isolation under nonreducing conditions, and we
showed previously that its MS analysis is facilitated by mutation
of a second, nonessential cysteine residue, Cys136, to glycine in
DprE1SM (
G136DprE1SM).
G136DprE1SM was incubated with
BTZ043 as well as FPR and after buffer exchange subjected to
MS analysis. We detected a protein with a mass of 51 656 Da,
which corresponds to the mass of 51 657 Da expected for the
semimercaptal adduct, as well as unmodified G136DprE1SM
(Figure 3A). On the basis of peak intensities, the ratio of
labeled G136DprE1SM to unlabeled
G136DprE1SM was 3.5:1.
The incubation of semimercaptals with an excess of thiols is
known to yield the corresponding hydroxylamines and
amines.11 We therefore analyzed the products resulting from
incubation of the covalent BTZ043−DprE1SM complex with
an excess of thiols. In agreement with the proposed formation
of a semimercaptal between BTZ043 and DprE1SM, we detected
the hydroxylamine and amine metabolites of BTZ043 in a
ratio of 1.2:1 (Figure S5B). Furthermore, ∼0.72 equiv of
BTZ metabolites was detected per molecule of DprE1SM
(Figure S5B).
The DprE1SM mutations Cys394Gly and Cys394Ser result in
resistance of M. smegmatis toward BTZ043,4 and G394DprE1SM
is not modified by BTZ043 (Figure 2D). We therefore
speculated that G394DprE1SM and
S394DprE1SM could func-
tion as multiturnover nitroreductases. Overnight incubation of
G394DprE1SM or
S394DprE1SM with 25 μM BTZ043 and 200 μM
FPR, subsequent protein precipitation, and analysis of the super-
natant by HPLC resulted in the detection of the corresponding
hydroxylamine and amine in yields of 4−30% (Figure 3B).
For both mutants, no significant amounts of reduction products
were detected in the absence of FPR (Figure S6). Furthermore,
wild-type DprE1SM yielded no significant amount of either the
amine or hydroxylamine under these conditions (Figure 3B).
This indicates that the suicide inhibition of DprE1SM is highly
efficient. A possible explanation for the observed difference
between the product ratios for G394DprE1SM and
S394DprE1SM
might be attributable to mutations of the active-site residue
Cys394 that affect the substrate specificity of DprE1SM.
In summary, we have reported on the characterization of
DprE1SM and DprE2SM from M. smegmatis, key enzymes for
cell-wall biogenesis, and the inactivation of DprE1SM by
BTZ043. The high degree of sequence identity of DprE1SM
and DprE2SM with the orthologous proteins from M.
tuberculosis and the fact that the same DprE1 mutations render
both bacteria resistant to BTZs indicate that the mechanism of
action of BTZs is identical in these two cases. To the best of
our knowledge, BTZs represent the first example of suicide
substrates that are activated through reduction of a nitro group
(Figure 4). It is noteworthy that the trapping of the nitroso
derivative by the active-site residue of DprE1SM occurs in a
near-quantitative manner, providing a rationale for the
extremely low MIC of BTZ043. Our data thus provide detailed
insights into the mechanisms of BTZ sensitivity and resistance
and represent an important step in the development of BTZs as
tuberculosis drugs.
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Figure 3. Interactions of DprE1SM,
G136DprE1SM,
G394DprE1SM, and
S394DprE1SM with BTZ043. (A) MS of
G136DprE1SM after incubation
with FPR (200 μM) and BTZ043 (20 μM) for 1 h at 37 °C.
(B) Concentration of BTZ043 metabolites identified after incubation
of DprE1SM,
G394DprE1SM, or
S394DprE1SM (5 μM) with BTZ043
(25 μM) in the presence of FPR (200 μM). Blue bars: hydroxyl-
amine derivative of BTZ043; red bars: amine derivative of BTZ043.
Error bars represent standard deviations of two independent
experiments.
Figure 4. Mechanism of BTZ sensitivity and resistance. Reduction of
the nitroso intermediate by BTZ-resistant DprE1 mutants requires
regeneration of FADH2, i.e., through oxidation of DPR to DPX.
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